Efficacy and Safety of Colchicine for the Prevention of Postoperative Atrial Fibrillation Among Patients Undergoing Major Cardiothoracic Surgery: A Meta-analysis and Meta-regression of Randomized Controlled Trials.
Frederick Berro RiveraSung Whoy ChaJohn Paul ApareceSathika JariyatamkittiMamas Andreas MamasPublished in: Journal of cardiovascular pharmacology (2024)
The role of colchicine for the prevention of postoperative atrial fibrillation (POAF) after cardiothoracic surgery is not well-established. We aimed to evaluate its potential in preventing POAF using data from randomized controlled trials (RCTs). A literature search was performed to identify studies reporting POAF as an outcome after cardiac or thoracic surgery in adult patients randomized to either colchicine or placebo. Primary outcome measured was incidence of POAF. Secondary outcomes included gastrointestinal (GI) adverse effects, sepsis, and length of stay. Subgroup analyses based on treatment durations and type of surgery were also performed, as well as regression analyses to control for covariates. We identified a total of 5377 patients (colchicine = 2,689, placebo = 2688). Although colchicine use was associated with a significantly reduced risk of POAF, risk of GI adverse effects were significantly higher. The rates of infection and length of stay were similar across the groups. Subgroup analyses showed that colchicine was effective for POAF prevention in cardiac surgery, but not in thoracic surgery. Prevention of POAF and incidence of GI adverse effects were similar in short-term and long-term colchicine treatment. Colchicine significantly reduces the incidence of POAF in patients undergoing cardiac surgery, but not in thoracic surgery.
Keyphrases
- thoracic surgery
- patients undergoing
- cardiac surgery
- minimally invasive
- atrial fibrillation
- acute kidney injury
- phase iii
- coronary artery bypass
- risk factors
- double blind
- end stage renal disease
- randomized controlled trial
- systematic review
- heart failure
- clinical trial
- newly diagnosed
- open label
- chronic kidney disease
- left atrial
- ejection fraction
- emergency department
- type diabetes
- metabolic syndrome
- left atrial appendage
- surgical site infection
- placebo controlled
- oral anticoagulants
- peritoneal dialysis
- deep learning
- phase ii
- weight loss
- patient reported outcomes
- replacement therapy
- patient reported